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ABSTRACT
Clinical trials are critical to improve AML treatment. It remains, however, unclear 
if clinical trial participation per se affects prognosis and to what extent the patients 
selected for trials differ from those of patients receiving intensive therapy off-trial. 
We conducted a population-based cohort study of newly diagnosed Danish AML 
patients treated with intensive chemotherapy between 2000–2013. We estimated 
accrual rates and compared characteristics, complete remission (CR) rates, and 
relative risks (RRs) of death at 90-day, 1-year, and 3-years in clinical trial patients 
to patients treated off-trial. 
Of 867 patients, 58.3% (n = 504) were included in a clinical trial. Accrual rates 
were similar across age groups (p = 0.55). Patients with poor performance status, 
comorbidity, therapy-related and secondary AML were less likely to be enrolled 
in trials. CR rates were 80.2% in trial-patients versus 68.6% in patients treated 
off- trial. Also, trial-patients had superior survival at 1-year; 72%, vs. 54% (adjusted 
RR of death 1.28(CI = 1.06–1.54)), and at 3 years; 45% vs. 29% (adjusted RR 
1.14(CI = 1.03–1.26)) compared to patients treated off-trial. 
Despite high accrual rates, patients enrolled in clinical trials had a favorable 
prognostic profile and a better survival than patients treated off-trial. In conclusion, 
all trial results should be extrapolated with caution and population-based studies of 
“real world patients” have a prominent role in examining the prognosis of AML.
INTRODUCTION
Randomized controlled trials contribute greatly to 
the understanding and improvement of the prognosis in 
acute myeloid leukemia (AML) and are the foundation 
of establishing new standard treatment regimens and 
clinical guidelines. However, to be able to extrapolate 
these data, the characteristics of the trial population must 
correspond to the general patient’s clinical and biological 
characteristics. [1]  
It is well described, that specific patient groups 
including ethnic minorities, subjects of low socioeconomic 
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status, elderly, and teenagers are underrepresented in 
oncology clinical trials. [2–4] Although, accrual rates to 
clinical trials for hematologic malignancies have consistently 
exceeded accrual rates for solid tumor trials, [1, 5, 6] older 
patients with acute leukemia remain underrepresented in 
clinical trials.  [1, 5, 7]  The proportion of eligible patients 
not included in any given study is rarely known, but a recent 
study suggested that clinical AML studies have become 
more selective over time as a consequence of more stringent 
in- and exclusion criteria that limit enrollment of patients 
less likely to respond to therapy. [8] 
During the last decade only one study has 
investigated both accrual rates and differences in 
characteristics between patients enrolled in AML trials 
and patients treated off-trial. However, the study included 
previously untreated, relapsed and primary refractory 
patients and did not stratify the results by treatment intent 
or disease state. Moreover, no outcomes were reported. [5]  
To investigate how patients selected for clinical 
trials differ from “real world patients”, we conducted a 
national population-based cohort study. We determined 
accrual rates and compared patient and clinical 
characteristics as well as prognosis in newly diagnosed 
AML patients enrolled in trials to those treated off-trial 
at a time where an age-appropriate trial was open. Using 
the Danish National Leukemia Registry (DNLR)[9], we 
compared younger and older patients treated with curative 
intent by intensive chemotherapy within phase III clinical 
trials in Denmark with patients treated off-protocol 
according to clinical characteristics, known prognostic 
factors, complete remission (CR) rate, and survival. 
RESULTS 
Patient characteristics 
We excluded patients with non-intensive therapy 
(best supportive care, n = 1141, low-dose chemotherapy, 
n = 347), patients < 18 years (n = 7), no protocol at time 
of diagnosis (n = 622), or no protocol at the treating 
institution (n = 71). The selection of the study population 
is shown in Figure 1 .
The final study population consisted of 867 adult 
AML patients treated with intensive chemotherapy in 
Denmark between 2002–2013. Of these, 58.3% (n = 504) 
were included in the three UK NCRI-sponsored clinical 
trials. 190 patients participated in the Medical Research 
Council (MRC) AML trial 15, (AML15), 161 patients 
participated in the National Cancer Research institute 
(NCRI) AML and high risk MDS (myelodysplastic 
syndrome) trial 16, (AML16), and 153 patients 
participated in the AML or high-risk myelodysplastic 
syndrome 17 trial (AML17). [10] Except for age 
guidelines and inclusion of high-risk MDS patients in 
AML16 and AML17, the in- and exclusion criteria for the 
three NCRI trials were almost identical (Table 1).
The AML15 trial included 61% of patients younger 
than 60 years eligible for intensive therapy during the 
study period, compared to 57% in the AML17. The 
AML16 trial recruited 56% of eligible patients 60 years or 
older. The accrual rates did not differ between age groups 
(p = 0.55), but for each trial accrual rate increased over 
time (p < 0.001) (accrual rate by year and by patient age, 
Figure 2). The accrual rate differed significantly between 
treating institutions, ranging from 41% to 70% (p < 0.001).
Overall, median age was 57 years (range 18–80) 
and 56% were men. The median follow-up time was 532 
days (range 0–4388 days). Patients still alive at the end of 
the study had a minimum follow-up time of 283 days. The 
characteristics of patients by trial status overall, and by age 
(< 60 versus ≥ 60 years) are presented in Table 2. Patients 
enrolled in the trials had fewer adverse prognostic features 
than patients treated outside the clinical trial setting. In 
such, patients who presented with worse performance 
status (PS), white blood cell count (WBC) > 50 mia/l, and 
lactate dehydrogenase (LDH) > 500 U/l, non-leukemia-
related comorbidity, tAML (treatment-related AML), and 
secondary AML (sAML) were less likely to be enrolled in 
the clinical trials. However, in multivariate analysis, non-
leukemia-related comorbidity was not associated with being 
treated with standard regimens outside clinical trials. When 
stratified by age, only tAML had an overall impact on trial 
inclusion in younger patients. Otherwise, estimates did not 
differ between age groups (results presented in Table 3).
Treatment and treatment response
Time to treatment initiation did not differ 
between patients treated on- or off-trial (median 3 days 
(interquartile range; IQR 1–7)). Twelve patients (33% of 
these enrolled on trials) died before treatment initiation. 
Compared to patients treated off-trial, trial patients 
were most likely to receive DA/ADE, with or without 
addition of Gemtuzumab ozogamicin (Mylotarg®) or 
FLT-3 inhibitor (> 92% versus 33%), and FLAG-based 
regimens (8% versus 4%). Patients treated off-trial more 
often received cytarabine in combination with idarubicin 
(56%) or mitoxantrone (7%). Trial patients more often 
received the planned full-dose second induction regimen 
than patients treated off-trial (96% versus 88%, p < 0.001). 
Patients enrolled in trials were also more likely to 
achieve CR than patients treated outside clinical trials 
(CR rates and crude ORs, overall and by age are shown 
in Table 4, Online Only). The overall CR rate in patients 
enrolled on a trial was 80.2% compared to 68.6% in 
patients treated off-trial (odds ratio 0.54 (CI = 0.40–0.74)). 
After adjustment for other factors known to impact CR 
rates, the effect of clinical trial participation diminished 
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(odds ratio 0.78 (CI = 0.55–1.12)). Though older patients 
in general were less likely to obtain CR (< 60 years; 80.8% 
versus ≥ 60 years: 68.3%), stratifying result by age group 
did not change the conclusions. 
Trial patients were more likely to undergo allogeneic 
hematopoietic stem-cell transplantation (alloHSCT) 
in first CR (23% versus 17% in patients < 60 years and 
23% versus 8% in patients ≥ 60 years). When restricting 
analysis to patients achieving a CR and adjusting for 
difference in cytogenetic risk group, comorbidity burden, 
age, and PS, the likelihood of undergoing transplantation 
remained higher in trial participants for both younger 
(adjusted OR 1.93 (CI = 1.07–3.48)) and older patients 
(adjusted OR 3.88 (CI = 1.58–9.58)).
Survival, overall and by age
The crude overall 90-day survival was higher in 
trial patients than in patients treated off-trial (90% versus 
83%, OR 1.72 (CI = 1.22–2.42)), but the difference 
could be explained by the different distribution of 
poor risk features (adjusted RR 1.11 (CI = 0.68–1.82)). 
Crude survival according to trial status and by age are 
presented in Figure 3 (survival rates) and in Table 5 
(crude and adjusted RRs of death at 90 days, 1 year, and 
3 years).
One-year survival was superior in clinical trial 
patients; 72%, compared with 54% in patients treated 
off-trial (< 60 years: 80% vs. 64%, ≥60 years; 61% vs. 
45%), corresponding to an adjusted overall RR of death 
in patients treated off-trial of 1.28 (CI = 1.06–1.54) 
compared with clinical trial patients. A difference, albeit 
smaller, in survival remained present at 3 years (overall 
adjusted RR 1.14 (CI = 1.03–1.26)). 
We performed several sensitivity analyses to test the 
robustness of our results. In a propensity score-matched 
survival analysis the estimates did not change our conclusions. 
Restricting the survival analysis to years with high accrual 
rate (2004–2012), did not significantly affect results. Also, 
adjusting for treating institution did not change results in any 
of the survival analysis. We performed a subgroup analysis 
restricting the survival analysis to de novo AML patients only 
Figure 1: Flowchart of patient selection for the study. Patients diagnosed at a time where no age-appropriate trial was open were 
excluded from the study. All information was obtained from the Danish National Leukemia Registry (DNLR), the Danish National Registry 
of Patients, and clinical trial office registries. The DNLR contains detailed and valid clinical information on all AML patients (completeness 
99.6%) diagnosed in Denmark since 2000. [9]
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(n = 605). The results do not deviate from the adjusted results 
reported for the overall cohort (results not shown).
DISCUSSION
Results of this study show that patients enrolled in 
three large UK NCRI AML trials in Denmark had fewer 
adverse prognostic features compared to AML patients 
intensively treated off-trial. When adjusting for these 
differences, however, no differences in complete remission 
and induction mortality were observed, but both younger 
and older trial patients had superior survival compared to 
patients treated off-trial.
To our knowledge, this study, containing virtually 
complete data on all AML patients treated in Denmark 
over more than a decade, is the largest study comparing 
Table 1: Inclusion and exclusion criteria of the clinical randomized phase III trials in Denmark 
2000–2014
Inclusion criteria Exclusion criteria
AML151 Diagnosis of AML as defined by the WHO 
Classification 
Considered suitable for intensive 
chemotherapy
Age < 60 years, but patients ≥ 60 years 
eligible if intensive therapy is considered a 
suitable option 
Written informed consent
Previous cytotoxic chemotherapy for AML (except for 
hydroxyurea, or similar low-dose therapy, to control the white 
count prior to initiation of intensive therapy) 
Blast transformation of chronic myeloid leukemia (CML) 
Active malignant disorder 
Pregnant or lactating
AML162 Diagnosis of AML (excluding promyelocytic 
leukemia) as defined by the WHO 
Classification or high risk myelodysplastic 
syndrome ((RAEB-2, defined as > 10% bone 
marrow blasts) 
Age > 60 years, but younger patients eligible 
if not considered fit for the MRC AML15 
trial. 
Written informed consent
Previous cytotoxic chemotherapy for AML (except for 
hydroxyurea, or similar low-dose therapy, to control the white 
count prior to initiation of intensive therapy) 
Blast transformation of chronic myeloid leukemia (CML) 
Active malignant disorder  (excluding basal cell carcinoma)
Patients with abnormal liver function tests exceeding twice the 
local upper limit of normal are not eligible for the Mylotarg® 
randomizations 
Patients with a serum creatinine above the local upper limit of 
normal are not eligible for the clofarabine randomizations 
Pregnant or lactating
AML173 Diagnosis of AML as defined by the WHO 
Classification or high risk myelodysplastic 
syndrome (RAEB-2; defined as > 10% bone 
marrow blasts) 
Age < 60 years, but patients over 60 years 
eligible if intensive therapy is considered a 
suitable option 
Written informed consent
Previous cytotoxic chemotherapy for AML (except for 
hydroxyurea, or similar low-dose therapy, to control the white 
count prior to initiation of intensive therapy) 
Blast transformation of chronic myeloid leukemia (CML) 
Active malignant disorder 
Pregnant or lactating 
Patients with abnormal liver function tests exceeding twice the 
local upper limit of normal are not eligible for the Mylotarg® 
randomizations
1 Medical Research Council (MRC) AML trial 15 
2 National Cancer Research institute (NCRI) AML and high risk MDS (myelodysplastic syndrome) trial 16 
3 AML or high-risk myelodysplastic syndrome 17 trial (AML17)
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baseline characteristics and prognosis of AML patients 
treated with intensive chemotherapy on clinical trials to 
patients treated off-trial. Linkage of high-quality data from 
national and local clinical and administrative registries 
offered the opportunity to estimate true accrual rates of 
the large UK NCRI AML trials in a truly population-
based setting. A high quality of data used for the study 
has previously been confirmed through different validation 
processes, [9, 11–13] and additional confirmation of trial 
status using centralized clinical trial office data further 
minimized misclassification. Essentially complete follow-
up data minimized the risk of selection bias in terms of our 
study aims and adjustment, stratification, and matching for 
clinically important variables reduced confounding. 
Accrual rates of the UK NCRI AML trials activated 
in Danish institutions match recent accrual rates reported 
for HOVON AML trials (68% in patients 18–40 years, 
and 57% in patients 41–60 years) [14] and exceed accrual 
rates of 44–45% previously reported by two AML studies, 
[1, 5] In contrast to the previous studies, we did not find 
Table 2: Patient characteristics according to age and trial status
Patients < 60 years, n = 507 Patients, ≥ 60 years, n = 360
Trial Off-trial Trial Off-trial
n = 301 (59.4%) n = 206 (40.6%) n = 203 (56.4%) n = 157 (43.6%)
Patient characteristics 
Sex, men, no. (%) 151 (50.2) 109 (51.6) 130 (64.1) 92 (58.6)
Age, median, years, median (range) 48 (18–59) 49 (18–59) 66 (60–79) 66 (60–80)
Numbers of Comorbidities, numbers1, (%)
     0 254 (84.4) 162 (78.6) 137 (67.5) 91 (57.9)
     1 36 (12.0) 30 (14.6) 47 (23.2) 47 (30.0)
   ≥ 2 11 (3.6) 14 (6.8) 19 (9.4) 19 (12.1)
WHO PS, no. (%)
     0 147 (48.8) 75 (36.4) 85 (41.9) 41 (26.1)
     1 127 (42.2) 89 (43.2) 96 (47.3) 83 (52.9)
   ≥ 2 27 (9.0) 42 (20.4) 22 (10.8) 33 (21.2)
tAML, no. (%) 8 (2.7) 20 (9.7) 14 (6.9) 12 (7.6)
sAML, no. (%) 18 (6.0) 30 (14.6) 28 (12.7) 35 (23.2)
Disease characteristics
Time to treatment, median (IQR) 2 (1–6) 3 (1–7) 5 (2–9) 4 (1–8)
Blast count marrow, %, median (IQR) 60 (37–81) 62 (40–82) 50 (30–75) 50 (30–75)
Blast count blood, %, median (IQR) 29 (6–67) 35 (10–70) 21 (2–61) 25 (6–58)
White Blood Count, x109/L, median (IQR) 11 (3–37) 17 (3–55) 8 (2–40) 18 (4–67)
Platelet count, x109/L, median (IQR) 55 (33–106) 44 (27–82) 57 (30–93) 52 (29–90)
Lactate Dehydrogenase, U/l2, median (IQR) 391 (224–639) 455 (243–1085) 320 (211–520) 491 (266–1000)
Extra-medullary disease, no. (%) 43 (14.6) 32 (15.9) 20 (10.2) 12 (8.1)
Cytogenetics risk group, MRC 2010, no. (%) 
     Favorable risk 32 (11.4) 17 (9.4) 8 (4.3) 0 (0.0)
     Intermediate risk 199 (71.1) 118 (65.2) 135 (71.8) 110 (77.5)
     Adverse risk 49 (17.5) 57 (25.4) 45 (23.9) 32 (22.5)
     Missing 21 25  15  15
Cytogenetics, karyotype, no. (%)
      Normal karyotype 140 (50.0) 78 (43.1) 104 (54.7) 72 (50.0)
      Abnormal karyotype 140 (50.0) 103 (57.0) 86 (45.3) 72 (50.0)
Abbreviations: WHO PS, World Health Organization Performance Status; tAML, therapy-related AML; sAML, secondary AML; 
IQR, Interquartile range (25–75 centiles); MRC, Medical Research Council
1According to the modified Charlson’s Comorbidity Index, which includes non-leukemia-related comorbidity
2  Normal range LDH: 105 to 205 U/L for patients < 70 years old, 115 to 255 U/L for patients ≥ 70 years old (randomly 
missing: n = 236)
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Figure 2: Accrual rates by age and over time. Trial inclusion by age groups (A), accrual rates per calendar year (B), and accrual 
rates by consecutive years since trial opening (C) The accrual rates did not differ between age groups (Cochran-Armitage Test for Trend, 
p = 0.55), but accrual rates increased both with time (B) and the longer a trial remained open (C), (Cochran-Armitage Test for Trend, 
p < 0.001).
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accrual rates in intensively treated patients to vary by sex 
or to decrease with age. [3, 7, 14–16] We speculated that 
the high accrual rate in our cohort reflect less restrictive 
in- and exclusion criteria in UK NCRI AML trials. Also, 
most prior studies comparing characteristics and prognosis 
in cancer patients treated on and off-trial included patients 
regardless of treatment intent. Historically, most trials 
have investigated intensive therapy, thus comparing trial 
patients to all patients treated outside off clinical trials, 
would clearly generate bias towards a greater difference 
Table 3: Patients and disease characteristics associated with clinical trial enrollment
Patients 
and Disease 
Characteristics
Overall Patients < 60 years Patients ≥ 60 years
Crude OR 
 (95%CI)
Adjusted OR1
 (95%CI)
Crude OR 
 (95%CI)
Adjusted OR1
 (95%CI)
Crude OR 
 (95%CI)
Adjusted OR1
 (95%CI)
Sex, men 1.02 (0.77 – 1.33) 1.01 (0.76 – 1.34) 0.90 (0.68 – 1.31) 0.90 (0.62 – 1.31) 1.26 (0.82 – 1.93) 1.21 (0.77 – 1.90)
Age, years 1.00 (0.99 – 1.01) 1.00 (1.00 – 1.02) 1.00 (0.98 – 1.02) 1.01 (0.99  -1.03) 0.97 (0.93 – 1.02) 0.97 (0.92 – 1.02)
WHO PS
     0 1 1 1 1 1 1
     1 0.65 (0.48 – 0.88) 0.67 (0.49 – 0.91) 0.73 (0.49 – 1.07) 0.78 (0.52 – 0.16) 0.56 (0.35 – 0.90) 0.54 (0.33 – 0.87)
   ≥ 2 0.32 (0.21 – 0.50) 0.35 (0.23 – 0.56) 0.33 (0.19 – 0.57) 0.35 (0.19 – 0.62) 0.32 (0.17 – 0.62) 0.36 (0.18 – 0.71)
s-AML, Y/N 0.46 (0.30 - 0.69) 0.42 (0.28 – 0.64) 0.37 (0.20 – 0.69) 0.29 (0.16 – 0.57) 0.56 (0.32 – 0.96) 0.53 (0.29 – 0.94)
t-AML, Y/N 0.47 (0.27 – 0.83) 0.49 (0.27 - 0·89) 0.25 (0.11 – 0.59) 0.23 (0.09 – 0.58) 0.89 (0.40 – 1.99) 0.96 (0.40 – 2.30)
White Blood Count, x109/L
     0–2 0.94 (0.62 – 1.42) 0.95 (0.62 – 1.45) 0.83 (0.48 – 1.43) 0.80 (0.45 – 1.41) 1.11 (0.60 – 2.09) 1.10 (0.57 – 2.11)
     2–10 1 1 1 1 1 1
    10–50 0.83 (0.57 – 1.20) 0.93 (0.63 – 1.36) 0.86 (0.53 – 1.38) 0.95 (0.57 – 1.56) 0.79 (0.44 – 1.42) 0.84 (0.46 – 1.54)
     ≥ 50 0.56 (0.38 – 0.81) 0.66 (0.44 – 0.97) 0.59 (0.42 – 0.96) 0.66 (0.39 – 1.10) 0.53 (0.30 – 0.95) 0.62 (0.33 – 1.14)
LDH ≥ 500 U/I 0.47 (0.35 – 0.61) 0.48 (0.35 – 0.67) 0.45 (0.31 – 0.65) 0.48 (0.31 – 0.72) 0.45 (0.29 – 0.66) 0.47 (0.28 – 0.80)
Comorbidity, Y/N 0.66 (0.49 – 0.90) 0.79 (0.56 – 1.11) 0.68 (0.43 – 1.07) 0.98 (0.58 – 1.67) 0.66 (0.43 – 1.02) 0.68 (0.43 – 1.08)
Logistic regression analysis, crude and adjusted odds ratios (ORs)
Abbreviations: CI, confidence interval; WHO PS, World Health Organization Performance Status; t-AML, therapy-related 
AML; s-AML, secondary AML; 
LDH, lactate dehydrogenase
Age includes as continuous variable, platelet count and marrow blast count included as continuous variables on a logarithmic scale
1 Adjusted for age, sex, WHO PS, sAML, tAML, WBC, LDH, and comorbidity
Table 4: Complete remission (CR) rates and chance of CR (odds ratio; OR) by protocol status, 
overall and stratified by age
CR (%) Crude OR (95%CI) Adjusted OR1 (95%CI)
All patients
     Trial 404 (80.2) 1 1
     Off-trial 249 (68.6) 0.54 (0.40 – 0.74) 0.78 (0.55 – 1.12)
< 60 years
      Trial 256 (85.1) 1 1
      Off-trial 151 (73.3) 0.48 (0.31 – 0.75) 0.66 (0.40 – 1.12)
≥ 60 years
      Trial 148 (72.9) 1 1  
      Off-trial 98 (62.4) 0.62 (0.39 – 0.96) 0.89 (0.53 – 1.50)
Abbreviations: CI, confidence interval
1Adjusted for age (continuous variable), sex, white blood cell count (logarithmically transformed continuous variable), 
cytogenetic risk profile (favorable, intermediate, and adverse), WHO PS (0, 1, 2, and ≥ 3), numbers of non-AML-related 
comorbidities (0, 1 and ≥ 2), sAML, and tAML
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Figure 3: Survival in AML patients by trial status. Kaplan Meier Plots with 95%CI bands for the study population overall (A), in 
patients younger than 60 years (B), and in patients 60 years or older (C).
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in baseline characteristics and outcome between on- and 
off-trial patients and may partly explain lower accrual 
rates in some previous reports. Herein, we restricted the 
study population to patients homogeneously treated with 
intensive therapy and harmonized according to treatment 
intent and period of diagnosis.
In addition, clinical trial enrollment in our cohort 
was not negatively affected by non-leukemia-related 
comorbidities, again reflecting nonrestrictive inclusion 
criteria for UK NCRI AML trials. This enables and 
encourages the physicians to enroll intensive therapy 
eligible patients with comorbidity into these trials and 
permits readily translation of clinical trial results to 
broader AML cohorts. Similar to previously observed, 
presence of sAML or tAML negatively impacted 
enrollment into clinical trials, [12] at least in part, due to 
risk of excessive anthracycline exposure. These findings 
limit our understanding on therapeutic effects in these 
subgroups of patient, when only focusing on clinical trial 
results.
Information regarding the generalizability of clinical 
trial results is important and can only be obtained from 
observational studies that include and compare patients 
treated on trial as well as off-trial. Our study shows that 
selection bias is present in the MRC trials enrollment 
within Danish centers, though most other trials have even 
stricter in- and exclusion. Therefore, It is reasonable to 
speculate that selection bias is introduced into almost 
every trial. Repeating this study in a setting with less 
inclusive trials would likely lead to lower accrual rates and 
an even more pronounced difference in characteristics and 
outcome between trial patients and off-trial patients. This 
hamper the external validity of these trials makes it crucial 
to consider patient characteristics of the trial population 
before referring results and treatment regimens to “real 
world patients.”
Generally, AML requires rapid initiation of treatment 
to avoid early deaths. Clinical trial screening can be an 
intense and time consuming process, which may impact 
time to treatment initiation or affect accrual rate in patients 
most in need for rapid therapy. Importantly, time to 
treatment did not differ between patients treated on and off- 
trial. It remains unclear, though, why patients with worse PS 
and elevated baseline WBC were less likely to participate 
in clinical trials, although physician preference may have 
influenced this decision. Another possible explanation is that 
patients acutely affected by disease or complications would 
be less likely to read the required material, understand trial 
concepts, and provide informed consent. 
It has previously been suggested that participation in 
a trial may confer a survival benefit independent of patient 
and disease characteristics as well as treatment. [17–20] 
Differences in outcome between patients treated in clinical 
trials compared to patients treated off trial can be due to 
three main factors; difference in baseline characteristics, 
difference in treatment modalities, and/or the effect 
of being enrolled in a trial (placebo effect, superior 
observation, and supportive care). Though, we found a 
significant difference in baseline characteristics in patients 
enrolled in trial and patients treated off-trial, adjusting or 
matching showed that these factors did not fully explain 
the superior survival found in trial patients. The UK NCRI 
AML trials did not dictate additional outpatient visits, 
specific supportive care, or treatment of complications and 
side effects different from standard treatment off-protocol 
that could explain the superior survival. 
The rather complex multifactorial designs of the 
UK NCRI trials allow numerous randomized questions 
to be addressed in one single trial, but so far, only a few 
experimental treatment arms have demonstrated improved 
overall survival compared to the control treatment 
(Supplementary Table S1). In our study, chemotherapy 
Table 5: The relative risk (RR) of death within 90-days, 1 year, and 3 years by trial status
90-days 1-year 3-years
Survival 
(%)
Crude RR 
(95%CI)
Adjusted RR1 
(95%CI)
Survival 
(%)
Crude RR 
(95%CI)
Adjusted RR1 
(95%CI)
Survival 
(%)
Crude RR  
(95%CI)
Adjusted RR1 
(95%CI)
All patients
     Trial 90 1 1 72 1 1 45 1 1
     Off-trial 83 1.72 (1.22 – 2.42) 1.11 (0.68 – 1.82) 54 1.66 (1.38 – 1.98) 1.28 (1.06 – 1.54) 29 1.29 (1.16 – 1.44) 1.14 (1.03 – 1.26)
< 60 years
     Trial 94 1 1 80 1 1 56 1 1
     Off-trial 85 2.52 (1.44 – 4.38) 1.04 (0.51 – 2.13) 60 1.94 (1.46 – 2.57) 1.44 (1.03 – 2.01) 39 1.39 (1.17 – 1.65) 1.17 (0.99 – 1.39)
≥ 60 years
     Trial 84 1 1 61 1 1 30 1 1
     Off-trial 80 1.25 (0.81 – 1.95) 0.79 (0.29 – 2.15) 45 1.41 (1.12 – 1.76) 1.21 (0.98 – 1.51) 17 1.19 (1.06 – 1.33) 1.09 (0.98 -1.22)
Abbreviations: CI, confidence interval 
1Adjusted for age (continuous variable), sex, white blood cell count (logarithmically transformed continuous variable), 
cytogenetic risk profile (favorable, intermediate, and adverse), WHO PS (0, 1, 2, and ≥ 3), numbers of non-AML-related 
comorbidities (0, 1 and ≥ 2), sAML, and tAML
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regimens differed between the two groups as more patients 
treated off-trial received idarubicin-containing induction 
therapy, whereas trial-patients most often received 
daunorubicin plus cyterabine with or without etoposide 
(DA or ADE). The AML15 showed that DA and ADE are 
comparable. [21] Also, mitoxantrone-containing induction 
regimens have been found to be comparable to DA in 
respect of CR-rates and OS. [22] Gemtuzumab ozogamicin 
more often used in trial-settings showed a marginal overall 
survival benefit at 3-years in older patients in the AML16, 
[23] but in AML15, the survival benefit was only found 
in favorable risk AML. [24] When comparing FLAG-Ida 
to DA/ADE, only the few patients receiving a total of 4 
courses had a significantly better overall survival. [21] 
More patients treated on-trial had a alloHSCT in 
first CR compared to off-trial patients. AlloHSCT was not 
a part of the randomization in the UK NCRI trials, but 
Russell et al. recently showed superior overall survival 
in reduced intensity conditioning alloHSCT recipients 
enrolled in AML15 for the subgroup of patients receiving 
a matched sibling graft compared to patients receiving 
consolidation chemotherapy. [25] 
Whether the survival benefit found in this study 
between patients treated off-trial and trial-patients 
regardless of treatment arm was due to trial inclusion in 
itself, due to difference in treatment especially higher 
frequencies of GO and alloHSCT, or due to unmeasured 
confounding cannot be adequately answered by this study. 
Reasons for declining participation in clinical 
trials are multifactorial and some patients may reject trial 
inclusion due to uncertainty of getting an adequate therapy. 
To improve general treatment outcomes in AML patients, 
including patients into investigational trials is crucial. Our 
observations that AML patients enrolled in randomized 
clinical trials had, at least, comparable outcomes to patients 
treated off-trial, could help assist patients in the decision 
process of considering enrollment on a clinical trial. 
Our study has limitations. Though we excluded all 
patients diagnosed when no suitable trial was open, we 
did not take into account shorter periods of trial closure, 
due to local reasons and issues, and to trial amendments. 
Since this type of bias will decrease accrual rates and lead 
relative estimates toward no association, this selection is 
likely of little significance. Importantly, the DNLR does 
not capture the reason for treating a patient off-trial. In 
relation to the UK NCRI AML trials in Denmark, reasons 
for opting-out may be disease-related, trial-related 
(exclusion criteria, fear off additional side effect from 
investigational drugs), due to physician and institutional 
factors, or patient-related factors (reluctance against trials 
or socioeconomic factors). Still, socioeconomic factors are 
thought to play a lesser role compared to previous findings 
in American studies, [3, 26] since health care including 
trial enrollment is free to all Danish citizens.
In summary, AML patients enrolled in the UK NCRI 
AML trials in Denmark had a more favorable profile than 
patients treated with standard intensive therapy regimens 
off-trial. Even after adjustment for the prognostic factors 
unevenly distributed between the two groups, trial 
participation remained associated with a significantly 
better survival; showing an 28% decreased risk of death 
at 1-year and an 14% decreased risk of death at 3-years. 
Since patient characteristics and outcomes in trial patients 
were not generalizable to intensive therapy patients, 
population-based studies continue to have an important 
role in examining aspects of treatment and prognosis of 
AML patients. 
MATERIALS AND METHODS 
We analyzed a cohort of all adult non-promyelocytic 
AML patients diagnosed in Denmark between January 
2000 and December 2013. The Danish population 
(approximately 5.7 million people) [27] is entitled free 
access to tax-supported medical health care. During the 
study period, AML patients were treated with intensive 
chemotherapy at only five highly specialized institutions. 
No treatment of hematological cancers takes place in 
private hospitals, which ensure uniform high-standard 
supportive care and treatment regimens to all patients. 
We excluded non-intensive chemotherapy patients 
with intensive therapy being defined as allocation to 
a remission induction regimen and an anthracycline 
or anthracycline-related compound (intention-to-
treat objective). Also, we excluded patients if no age-
appropriate trial was open at time of diagnosis (Flow 
chart for study selection, Figure 1). 
Clinical trials 
During the study period, newly diagnosed AML 
patients eligible for intensive therapy were enrolled into 
three randomized phase III trials (Table 1). Patients not 
fulfilling the age criteria could be included if the treating 
physician found the treatment offered by the protocol 
suitable for the given patient. The MRC AML15 was 
designed for patients younger than 60 years and opened at 
four out of five specialized centers in Denmark from 2002. 
The last patient was included in 2009. AML16 included 
primarily patients 60 years or older and was open at all 
specialized centers in 2007–2012. The AML17 replaced 
AML15 and opened in 2010 at all specialized centers 
and was still recruiting at end of the study period. The 
investigational treatment and a summary of the published 
results of the three trials are shown in Supplementary 
Table S1. 
Clinical data
We obtained all clinical information from the Danish 
National Leukemia Registry unless otherwise noted. The 
registry contains detailed and valid clinical information 
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on all AML patients (completeness 99.6%) diagnosed in 
Denmark since 2000. [9]
Date of diagnosis was defined as date of first 
diagnostic bone marrow examination. Cytogenetic 
results were grouped according to MRC’s 2010 revised 
criteria. [28] We validated information on clinical trial 
participation using centralized trial clinical office data. We 
obtained information on non-leukemia-related comorbidity 
(according to a modified version of the Charlson 
comorbidity Index; no comorbid disease, one comorbid 
disease, or ≥ 1 comorbid disease) from the Danish National 
Registry of Patients. [11]
Treatment outcome 
CR criteria were based on international consensus 
criteria for morphological CR after two cycles of induction 
chemotherapy. [29] We obtained information on all-cause 
mortality and immigration from the Civil Registration 
System. The Civil Registration System uses a unique civil 
registration number to track daily updated information on 
vital status and residence on all Danish residents. [30]
Statistical analyses
 We stratified descriptive data by clinical trial 
status and age. We computed prevalence of clinical trial 
accrual for all AML patients, and trends in participation 
by age, according to year of trial inclusion, and by treating 
institution (Cochran-Armitage Test for Trend). Treatment 
modalities and accessible trials differed for younger 
or older patients. For comparable groups, we therefore 
stratified all analyses by age ≤60 and >60 years since 
this cut-off was used in the UK NCRI AML trials. Trial 
participation was used as a reference, and all estimates 
included corresponding 95% confidence intervals (CIs). 
To assess the association between characteristics 
and clinical trial inclusion as well as the likelihood 
of allogeneic hematopoietic stem-cell transplantation 
performed in first CR by trial status, we used logistic 
regression analysis (Crude and adjusted odds ratios (ORs)).
Patients were followed from date of diagnosis until 
death, immigration, or end of follow up (Sep 22nd, 2014). 
Overall survival was described using Kaplan-Meier curves 
with 95% CI bands. To fit generalized linear models for 
crude survival we used a pseudo value approach and 
calculated pseudo values and crude and adjusted relative 
risks (RRs) of death at 90 days, 1 year, and 3 years. [31–
33] We adjusted for age, sex, cytogenetics, WHO PS, 
comorbidity, WBC, sAML, and tAML. 
To test robustness of the results, we repeated 
survival analyses adjusting and matching for propensity 
scores predicting probability to enter a trial conditional on 
age, sex, cytogenetics, PS, comorbidity, WBC, sAML, and 
tAML (552 patients matched 1:1 without replacement). 
[34, 35] Accrual rates varied between treating institutions, 
we therefore repeated all analyses with adjustment for 
treating institution. Also, we restricted survival analyses 
to years with high accrual rate. We additionally performed 
a subgroup analysis restricting the survival analysis to de 
novo AML patients only.
The study was approved by the Danish Data 
Protection Agency (j.nr. 2012–41–0878) and the National 
Board of Health (j.nr.3–3013–158). Analyses were 
conducted using Stata version13.1 software (STATA Corp, 
College Station, TX, USA).
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